idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
(umg/dzhk) For the first time, engineered heart muscle (EHM) from human induced pluripotent stem cells (iPSCs) will be used to treat patients with heart failure. After regulatory approval, recruitment of the first patient for the first-in-class, first-in-patient BioVAT-HF* early clinical trial has started in Göttingen, Germany. The trial is sponsored by the University Medical Center Göttingen and funded by the German Center for Cardiovascular Research (DZHK) and the Repairon GmbH. Additional participating centers include the University Medical Center Schleswig-Holstein in Lübeck and the Heart- and Diabetes Center of the Ruhr University of Bochum in Bad Oeynhausen.
For the first time, engineered heart muscle (EHM) from human induced pluripotent stem cells (iPSCs) will be used to treat patients with heart failure. After regulatory approval, recruitment of the first patient for the first-in-class, first-in-patient BioVAT-HF* early clinical trial has started in Göttingen, Germany. The trial is sponsored by the University Medical Center Göttingen and funded by the German Center for Cardiovascular Research (DZHK) and the Repairon GmbH. Additional participating centers include the University Medical Center Schleswig-Holstein in Lübeck and the Heart- and Diabetes Center of the Ruhr University of Bochum in Bad Oeynhausen.
Heart failure affects 60 million people worldwide. With current treatment and medical care, one out of five patients with heart failure will die within 12 months – there is no cure. This means that half of those diagnosed with heart failure today will not be alive in 5 years. The BioVAT-HF-DZHK20** Phase I/II clinical trial comes after 25 years of compre-hensive preclinical development, and is the first to investigate whether the implantation of a heart muscle patch, grown in a laboratory from stem cells, can safely and effectively repair the failing heart.
Approval of the BioVAT-HF-DZHK20 multicenter trial was granted by the Paul-Ehrlich-Institute at the end of 2020. The trial is scheduled to enroll 53 patients with advanced heart failure.
*BioVAT-HF: Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (ClinicalTrials.gov Identifier: NCT04396899)
**DZHK20: annex with running number of clinical trials supported by the German Center of Cardiovascular Research (DZHK); BioVAT-HF is the DZHK study #20 and the first DZHK early clinical trial testing an ATMP after comprehensive development through its translational research program at the Göttingen partner site of the DZHK.
Short description of Engineered Heart Muscle (EHM)
Engineered heart muscle (EHM) is prepared from human induced pluripotent stem cell (iPSC)-derived heart muscle cells and collagen. After 6 years of optimization and valida-tion of the manufacturing process as well as comprehensive safety and efficacy testing, following advice by the Paul-Ehrlich-Institute (the responsible authority for advanced medicinal products [ATMPs] in Germany), approval of manufacturing and clinical testing of the first pluripotent stem cell-derived innovative medicinal product (IMP) in Germany was granted by the competent authorities. The concept of tissue engineered heart repair with EHM as well as the protocols to produce EHM as an IMP were developed at the Institute of Pharmacology and Toxicology at the University Medical Center Göttingen, Germany, by Prof. Dr. Wolfram-Hubertus Zimmermann and colleagues. With evidence for safe and efficacious long-term retention in preclinical models, the first patients are recruited to investigate whether the preclinical observations translate to improve care in and ideally offer a cure to patients with advanced heart failure.
Additional information:
University Medical Center, Georg-August-University
Institute of Pharmacology and Toxicology
Prof. Dr. Wolfram-Hubertus Zimmermann
Robert-Koch-Straße 40
37075 Göttingen
Germany
Phone +49 551 39 65781
Fax +49 551 39 5699
Email: biovat.info@med.uni-goettingen.de
Web: https://biovat.dzhk.de/
Unternehmenskommunikation, Presse- und Öffentlichkeitsarbeit
Stefan Weller, Leiter
Von-Siebold-Str. 3, 37075 Göttingen
Phone +49 551 / 39-61020, Fax +49 551 / 39-61023
Email: presse.medizin@med.uni-goettingen.de
www.umg.eu
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Christine Vollgraf
Leiterin Öffentlichkeitsarbeit
DZHK-Geschäftsstelle Berlin, Potsdamer Str. 58, 10785 Berlin
Phone +49 030 / 3465 529-02
Email: christine.vollgraf@dzhk.de
www.dzhk.de
Institute of Pharmacology and Toxicology
Prof. Dr. Wolfram-Hubertus Zimmermann
Robert-Koch-Straße 40
37075 Göttingen
Germany
Phone +49 551 39 65781
Fax +49 551 39 5699
Email: biovat.info@med.uni-goettingen.de
Web: https://biovat.dzhk.de/
Engineered Heart Muscle (EHM)
umg/pharmacology
Engineered heart muscle (EHM) is prepared from human induced pluripotent stem cell (iPSC)-derived he ...
umg/pharmacology
Merkmale dieser Pressemitteilung:
Journalisten
Medizin
überregional
Forschungs- / Wissenstransfer, Forschungsergebnisse
Englisch
Engineered Heart Muscle (EHM)
umg/pharmacology
Engineered heart muscle (EHM) is prepared from human induced pluripotent stem cell (iPSC)-derived he ...
umg/pharmacology
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
